NCT06595186: JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
- State
- Under way
- Phase
- Phase 2
- People
- 25 planned
- Started
- 31 Oct 2022
- Primary completion
- 16 Aug 2026
- Arms
- Dose Escalation Cohort, Dose Expansion Cohort
- Results
- None posted
- 31 Oct 2022: Trial started
- 19 Sep 2024: Trial registered